At a Glance
- Company: Novo Nordisk Foundation; BioInnovation Institute (BII)
- Location: Copenhagen, Denmark (focus on Denmark/Europe)
- Deal value: DKK 5.5 billion (~US$850m) from 2026–2035
- Focus area: Early‑stage life sciences, AI, quantum computing in health/planetary resilience
- Next steps: Scale BII’s venture lab/bio studio to support 130+ startups
What happened?
The Novo Nordisk Foundation announced a commitment of up to DKK 5.5 billion (approximately US$850 million) to the BioInnovation Institute (BII) over 2026–2035, expanding support for early‑stage biotech and deep tech innovation across Denmark and Europe. BII, which the Foundation spun out in 2018, will use the funds to scale its venture lab, bio studio and quantum programmes.
Why does it matter?
Europe lags the US and China in translating research into commercial biotech success despite strong science, with seed/Series A funding declining amid risk aversion. This investment addresses the gap by providing infrastructure, networks and capital to more startups, potentially attracting co‑investors and strengthening Europe’s competitiveness in human health, planetary health and resilience technologies including AI/quantum.
Who’s behind it?
The Novo Nordisk Foundation manages Novo Holdings and philanthropic investments, redistributing pharma profits into science. BII has already created 130+ companies, attracted DKK 7bn+ external funding and supported ventures like Troya Therapeutics (protein engineering) and Sulis Therapeutics (STING inhibitors).
How was it achieved?
Funds will expand BII’s Copenhagen hub to support more entrepreneurs through early financing, infrastructure and business development, with geographic reach across Europe and new emphasis on AI/quantum projects. BII expects the capital to leverage additional private investment.
What’s next?
BII aims to increase annual startup support, deepen pan‑European partnerships and commercialise discoveries faster, running through 2035 to build sustained innovation capacity.
What are people saying?
Novo Nordisk Foundation CEO Mads Krogsgaard Thomsen: “This empowers BII as Europe’s powerhouse for innovation, driving growth and entrepreneurial culture.” BII CEO Jens Nielsen: “We cannot push innovation boundaries alone—strengthening partnerships ensures Europe’s competitiveness.”